Edition:
India

Kura Oncology Inc (KURA.OQ)

KURA.OQ on NASDAQ Stock Exchange Global Select Market

13.75USD
14 Dec 2017
Change (% chg)

$-0.15 (-1.08%)
Prev Close
$13.90
Open
$13.85
Day's High
$14.30
Day's Low
$13.50
Volume
58,232
Avg. Vol
151,075
52-wk High
$17.40
52-wk Low
$5.50

Select another date:

Fri, Nov 10 2017

BRIEF-Kura Oncology files for mixed shelf offering of up to $200 mln - SEC filing‍​

* Kura Oncology Inc - files for mixed shelf offering of up to $200 million - SEC filing‍​ Source text:(http://bit.ly/2yNnKBA) Further company coverage:

BRIEF-Kura Oncology Inc entered into amendment to its sales agreement with Cowen and Co

* Kura Oncology Inc - on Nov 9, 2017, co entered into amendment to its sales agreement, dated January 27, 2017 with Cowen and Company LLC ‍​-SEC filing

BRIEF-Kura Oncology reports third quarter 2017 financial results

* Kura Oncology reports third quarter 2017 financial results and provides corporate update

BRIEF-KURA ONCOLOGY ‍CONFIRMS PARTIAL RESPONSES OBSERVED IN PATIENTS WITH HRAS MUTANT HNSCC IN TRIAL

* KURA ONCOLOGY LEAD CANDIDATE TIPIFARNIB SHOWS DURABLE ANTI-TUMOR ACTIVITY IN HRAS MUTANT HEAD AND NECK CANCER IN AACR-NCI-EORTC UPDATE

BRIEF-Kura Oncology announces positive phase 2 study for Tipifarnib in HRAS mutant head and neck cancer

* Kura Oncology announces positive phase 2 study for Tipifarnib in HRAS mutant head and neck cancer

BRIEF-‍Great Point Partners LLC reports 5.92 percent passive stake ​in Kura Oncology Inc

* ‍Great Point Partners LLC reports 5.92 percent passive stake ​in Kura Oncology Inc as on August 11, 2017 - sec filing Source text: (http://bit.ly/2vXMuCE) Further company coverage:

BRIEF-Kura Oncology prices public offering of 7.70 mln common shares at $6.50 per share

* Kura oncology announces pricing of public offering of common stock

BRIEF-Kura Oncology announces commencement of public offering of common stock

* Kura Oncology announces commencement of public offering of common stock

BRIEF-Kura Oncology Q2 loss per share $0.40

* Kura Oncology reports second quarter 2017 financial results and provides update on Tipifarnib phase 2 study

BRIEF-Kura Oncology ‍enters into collaboration agreement with Foundation Medicine ​

* Kura Oncology Inc - ‍entered into a collaboration agreement with Foundation Medicine, Inc.​

Select another date: